T-shirts are the stuff of pop culture.
But as the first-of-its-kind, patented technology for creating wearable electronics, blue waves, blue fingers and other wearable technology, they are about to get a whole lot more real.
The world’s largest wearable technology company, Blue Wave Technologies, today announced that its patented technology, called Blue Finger, will become the most advanced medical device ever created and will be widely used in hospitals and healthcare facilities throughout the world.
Blue Finger is based on the latest advancements in wearable technology that include 3D sensing and 3D printing.
Blue Wave has been manufacturing Blue Finger devices for over 10 years, and it is expected to deliver more than 50,000 of these devices in 2020, according to the company.
The company’s first Blue Finger device is a $10,000 wristband, and Blue Wave is working on more innovative products.
“This is a big deal,” said Dr. Andrew Koehler, vice president of medical devices at Blue Wave.
“The technology is incredibly powerful, and we are able to scale it from a few hundred to a few thousand devices in just a few years.”
Blue Finger is a breakthrough in wearable electronics that uses 3D sensors to measure electrical activity, such as heart rate and skin conductance.
Blue Feild is a technology that uses the same sensor and software to analyze the blood flow to the wrist and finger.
The wearable is worn by a user on the wrist or hand, allowing the user to monitor and control the devices.
Blue Feild can monitor a person’s blood pressure, blood glucose levels, heart rate, breathing rate, heart beat and skin temperature, among other vital metrics.
The device also can detect skin friction and temperature, which can alert a physician or nurse on call.
Blue Finger uses advanced sensors and software developed by Blue Wave to create a personalized, wearable device.
Bluefeild is made by BlueWave’s proprietary software that analyzes the wearer’s body and compares the data with medical records.
BlueFeild can also measure electrical and mechanical activity and blood flow.
As a result, the Blue Feield can tell a person whether the wearer is exerting energy or not.
It also can identify whether a person is wearing gloves, which is necessary to keep the wearer safe while operating the device.
This next-generation Blue FeILD device uses 3-D sensing technology to measure the electrical activity of the wearer.
Using a combination of 3-d scanning and 3-sensor 3D imaging, Blue Feould can measure the wearer in a whole new way, enabling more accurate measurements.
The next generation Blue Feili is currently in production, and the company has plans to deliver 10,000 units to healthcare facilities in 2020.
Blue Feili has been tested in several hospitals in the U.S. and in Canada, with more than 100,000 users worldwide.
In order to create Blue Feile, BlueWave partnered with biotechnology company B.C. Biotech, which developed a novel sensor, known as a nanofiber, that is capable of measuring electrical activity and can be used to analyze blood flow, body temperature and skin friction.
The Blue Feiles are made from an injection mold and have a small, lightweight core.
BlueWave is able to print the nanofibers for about 50% of the cost of making the devices, while the rest of the manufacturing process takes place in-house.
BlueFeilds can measure up to 400 milliamps per square centimeter, a measurement that can be extremely accurate.
Blue-Feild’s sensor can also be used for heart rate monitoring.
Because BlueFeile can measure more than 400 millis, it can be worn on a patient’s wrist or finger.
Because it uses a 3-dimensional sensor, BlueFeiles can be implanted in a patient without having to remove the patient’s finger, which eliminates the need for a surgeon.
While Blue Feiling is only available in limited markets, Blue wave hopes that it will help healthcare providers to become more proactive in their patient care, and that the technology will ultimately help them to diagnose patients earlier.
For more information about Blue Wave, visit their website at www.bluewave.com and follow them on Twitter @BlueWaveNews.